

S6 Table. Pairwise comparisons among different diabetic duration subgroups in diabetic patients for TTFT and CSS

Log-rank test (Mantel-Cox)	Dataset	Diabetic duration (mo) ^{a)}	< 12		≥ 12 and < 48		≥ 48 and < 120		≥ 120	
			Chi-square	p-value	Chi-square	p-value	Chi-square	p-value	Chi-square	p-value
TTFT (overall p > 0.05)	Unmatched (complete) dataset	< 12	-	-	0.104	0.747	1.767	0.184	4.246	0.039
		≥ 12 and < 48	0.104	0.747	-	-	1.271	0.260	2.763	0.096
		≥ 48 and < 120	1.767	0.184	1.271	0.260	-	-	0.302	0.583
		≥ 120	4.246	0.039	2.763	0.096	0.302	0.583	-	-
	Propensity score-matched (1:1) dataset ^{b)}	< 12	-	-	0.703	0.402	2.702	0.100	2.291	0.130
		≥ 12 and < 48	0.703	0.402	-	-	0.684	0.408	0.310	0.578
		≥ 48 and < 120	2.702	0.100	0.684	0.408	-	-	0.051	0.821
		≥ 120	2.291	0.130	0.310	0.578	0.051	0.821	-	-
CSS (overall p < 0.01)	Unmatched (complete) dataset	< 12	-	-	5.799	0.016	15.497	<0.001	31.527	< 0.001
		≥ 12 and < 48	5.799	0.016	-	-	3.347	0.067	19.161	< 0.001
		≥ 48 and < 120	15.497	< 0.001	3.347	0.067	-	-	7.520	0.006
		≥ 120	31.527	< 0.001	19.161	< 0.001	7.520	0.006	-	-
	Propensity score-matched (1:1) dataset ^{b)}	< 12	-	-	5.925	0.015	13.592	<0.001	17.607	< 0.001
		≥ 12 and < 48	5.925	0.015	-	-	1.898	0.168	5.077	0.024
		≥ 48 and < 120	13.592	< 0.001	1.898	0.168	-	-	0.832	0.362
		≥ 120	17.607	< 0.001	5.077	0.024	0.832	0.362	-	-

TTFT, time-to-first-treatment; CSS, cancer-specific survival; β_2 -MG, β_2 -microglobulin; *IGHV*, immunoglobulin heavy chain variable region. ^{a)}Diabetic duration subgroups were categorized by quartiles (Q1=25%, Q2=50%, Q3=75%) of disease duration in diabetic patients, ^{b)}Propensity score-matched (1:1) analyses were performed with a small caliper of 0.1 for matching potential cofounders including age, Binet stage, β_2 -MG levels, *TP53* disruption, and *IGHV* mutational status, etc.